The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.
Frederique Madeleine Penault-Llorca
Consultant or Advisory Role - Genomic Health
Honoraria - Genomic Health
Thomas Filleron
No relevant relationships to disclose
Bernard Asselain
No relevant relationships to disclose
Frederick L. Baehner
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Pierre Fumoleau
Consultant or Advisory Role - Janssen; Novartis; Roche; Sanofi
Magali Lacroix-Triki
No relevant relationships to disclose
Steven M. Butler
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Farid Jamshidian
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Diana B. Cherbavaz
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Lise Roca
No relevant relationships to disclose
Christine Sagan
No relevant relationships to disclose
J Lemonnier
No relevant relationships to disclose
Anne-Laure Martin
No relevant relationships to disclose
Henri Hubert Roche
No relevant relationships to disclose